By Industry Standard Research
ISR’s annual CDMO Benchmarking research asks participants to identify the CDMO attributes that factor into their service-provider selection decisions. This year’s data point toward concerns about assurance of supply when it comes to sterile injectables among both small molecule and biologic drug product outsourcers. Having capacity to meet sponsors’ demands and reliable, on-time delivery occupy the top of the lists. This is not surprising, given the increase in demand for vaccine production brought about by the COVID-19 pandemic.